专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07781213B2 Method for producing dendritic cells 有权
标题翻译：树突状细胞的制备方法
公开(公告)号：US07781213B2
公开(公告)日：2010-08-24
申请号：US12326831
申请日：2008-12-02
申请人： Herman Waldmann , Paul J. Fairchild , Richard Gardner , Frances Brook
发明人： Herman Waldmann , Paul J. Fairchild , Richard Gardner , Frances Brook
IPC分类号： C12N5/071 , C12N5/00 , C12N5/02
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
摘要翻译：公开了胚胎干细胞衍生的树突状细胞，能够成熟的遗传修饰的未成熟树突状细胞，以及用于产生这种细胞的方法。在一个实施方案中，所制备的细胞通过包括以下步骤的方法产生：提供一群胚胎干细胞; 在细胞因子或细胞因子的组合存在下培养胚胎干细胞，其导致胚胎干细胞分化成树突状细胞; 并从培养物中回收树突状细胞。在另一个实施方案中，细胞可以被遗传修饰。

12. 发明申请

US20100015166A1 Therapeutic antibodies 有权
标题翻译：治疗性抗体
公开(公告)号：US20100015166A1
公开(公告)日：2010-01-21
申请号：US12316621
申请日：2008-12-15
申请人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
发明人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
IPC分类号： A61K39/395 , C07K2/00 , C07K16/00 , C07K19/00 , A61K38/02
CPC分类号： C07K16/2893 , A61K47/6849 , A61K2039/505 , C07K14/70592 , C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2318/10 , C07K2319/00
摘要： A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
摘要翻译：一种药物，其包含与治疗靶标相对的治疗性蛋白质，所述蛋白质用抑制蛋白质与治疗靶标结合的化合物修饰，所述修饰蛋白质有效降低针对所述蛋白质的免疫应答并产生治疗效果通过结合治疗靶标。治疗性蛋白质可以是包含结合治疗靶标的抗体结合位点的抗体。

13. 发明授权

US07473556B2 Method for producing dendritic cells 有权
公开(公告)号：US07473556B2
公开(公告)日：2009-01-06
申请号：US11789669
申请日：2007-04-24
申请人： Herman Waldmann , Paul J. Fairchild , Richard Gardner , Frances Brook
发明人： Herman Waldmann , Paul J. Fairchild , Richard Gardner , Frances Brook
IPC分类号： C12N5/00 , C12N5/02 , C12N5/06 , C12N5/10 , C12N15/00 , A01N63/00 , A61K48/00
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.

14. 发明申请

US20060018898A1 Antibody variants 有权
公开(公告)号：US20060018898A1
公开(公告)日：2006-01-26
申请号：US11180631
申请日：2005-07-14
申请人： Herman Waldmann , Lisa Gilliland , Masahide Tone , Mark Frewin , Louise Walsh
发明人： Herman Waldmann , Lisa Gilliland , Masahide Tone , Mark Frewin , Louise Walsh
IPC分类号： A61K39/395
CPC分类号： C07K16/465 , A61K38/00 , C07K16/2893 , C07K2317/24 , C07K2319/00
摘要： This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.

15. 发明授权

US06569430B1 Antibodies to the antigen Campath-1 失效
标题翻译：抗原的抗体Campath-1
公开(公告)号：US06569430B1
公开(公告)日：2003-05-27
申请号：US08407620
申请日：1995-03-21
申请人： Herman Waldmann , Michael R. Clark , Gregory P. Winter , Lutz Riechmann
发明人： Herman Waldmann , Michael R. Clark , Gregory P. Winter , Lutz Riechmann
IPC分类号： A61K39395
CPC分类号： C07K16/465 , A61K38/00 , C07K16/2893 , C07K2317/24 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.
摘要翻译：产生抗体，其与抗原Campath-1有效结合，并且其具有至少一个大鼠来源的互补决定区，如图1所示。 2，其可以与期望的一系列不同的外部可变结构域框架区域结合，包括人源的框架区域。

16. 发明授权

US6120766A CDW52-specific antibody for treatment of multiple sclerosis 失效
标题翻译：用于治疗多发性硬化的CDW52特异性抗体
公开(公告)号：US6120766A
公开(公告)日：2000-09-19
申请号：US244316
申请日：1994-06-22
申请人： Geoffrey Hale , Herman Waldmann
发明人： Geoffrey Hale , Herman Waldmann
IPC分类号： A61K39/395 , A61K31/57 , A61K38/00 , A61P37/00 , A61P37/06 , C07K16/28
CPC分类号： A61K31/57 , C07K16/2893 , A61K38/00
摘要： The invention relates to the use of an antibody recognizing the Cdw52 antigen in the treatment of multiple sclerosis. Preferably, the antibody is the humanized antibody in the humanized antibody CAMPATH-1H.
摘要翻译： PCT No.PCT / GB92 / 02252 Sec。 371日期：1994年6月22日 102（e）日期1994年6月22日PCT提交1992年12月4日PCT公布。公开号WO93 / 10817 日期1993年6月10日本发明涉及识别Cdw52抗原的抗体在治疗多发性硬化中的用途。优选地，抗体是人源化抗体CAMPATH-1H中的人源化抗体。

17. 发明授权

US5502167A CDR grafted humanised chimeric T-cell antibodies 失效
标题翻译： CDR移植人源化嵌合T细胞抗体
公开(公告)号：US5502167A
公开(公告)日：1996-03-26
申请号：US244626
申请日：1994-07-15
申请人： Herman Waldmann , Louise Walsh , James S. Crowe , Alan P. Lewis
发明人： Herman Waldmann , Louise Walsh , James S. Crowe , Alan P. Lewis
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P37/06 , C07K14/725 , C07K16/00 , C07K16/18 , C07K16/28 , C12N5/10 , C12N15/13 , C12P21/08 , C12R1/91 , A61K35/16 , A61K39/00
CPC分类号： C07K16/2806 , A61K38/00 , C07K2317/24 , Y10S530/867
摘要： A humanised antibody is provided in which the amino acid sequence of the CDRs is derived from the sequence of CDRs of a monoclonal antibody having the specificity of binding to resting and activated T-cells, inhibiting T-cell proliferation and lysing T-cells from mice transgenic for human CD2 and in which sufficient of the amino acid sequence of each CDR has been retained to provide the same specificity for the humanised antibody.
摘要翻译： PCT No.PCT / GB92 / 02251 Sec。 371日期：1994年6月3日 102（e）日期1994年6月3日PCT提交1992年12月4日PCT公布。公开号WO93 / 11237 日期：1993年6月10日。提供了人源化抗体，其中CDR的氨基酸序列衍生自具有结合静息和活化T细胞的特异性的单克隆抗体的CDR序列，抑制T细胞增殖以及从对于人CD2转基因的小鼠中裂解T细胞，并且其中保留了足够的每个CDR的氨基酸序列以提供与人源化抗体相同的特异性。

18. 发明申请

US20120282184A1 TREATMENT OF OBESITY 审中-公开
标题翻译：治疗肥胖
公开(公告)号：US20120282184A1
公开(公告)日：2012-11-08
申请号：US13504647
申请日：2010-10-29
申请人： Herman Waldmann , Kathleen Nolan , Lynn Poulton
发明人： Herman Waldmann , Kathleen Nolan , Lynn Poulton
IPC分类号： A61K39/395 , A61K49/00 , A61P3/04 , A61P3/10 , A61P3/00 , A61P3/06 , C07K16/28 , G01N33/573 , C12Q1/32 , C12Q1/52 , G01N33/68 , G01N27/72 , G01N33/66 , G01N33/92 , G01N33/64 , G01N33/74 , A61K38/17 , A61K38/28
CPC分类号： G01N33/6893 , A01K2227/105 , A01K2267/0362 , A61K38/00 , G01N2800/042 , G01N2800/044 , Y10T436/144444 , Y10T436/200833
摘要： A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies.
摘要翻译：一种用于预防或治疗选自2型糖尿病，肥胖症和代谢综合征的病症的方法，包括激活GITRL途径。用于筛选物质以治疗这些病症的方法，诊断或预测这些病症并选择和监测疗法。

19. 发明授权

US07994289B2 Humanized anti-CD3 antibodies 有权
标题翻译：人源化抗CD3抗体
公开(公告)号：US07994289B2
公开(公告)日：2011-08-09
申请号：US10463442
申请日：2003-06-18
申请人： Herman Waldmann , Mark Frewin
发明人： Herman Waldmann , Mark Frewin
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , C12P21/04
CPC分类号： C07K16/2809 , A61K38/00 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2319/00
摘要： An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.
摘要翻译：提供具有对CD3抗原复合物的结合亲和力的IgG抗体，其中在重链中具有可选区域框架以及选自SEQ ID No 2,4和6的氨基酸序列的至少一个CDR，并且各自保守修饰其轻链具有可变区框架以及选自SEQ ID No 8,10和12的氨基酸序列的至少一个CDR及其各自的保守修饰变体，其特征在于重链可变区框架依次对应涉及人类序列，轻链可变区框架包括啮齿动物型序列特征的一种或多种特定氨基酸。新型抗体能够以增强的产量被哺乳动物细胞表达系统表达。

20. 发明授权

US07947272B2 Compositions and methods of tolerizing a primate to an antigen 失效
标题翻译：将灵长类动物耐受抗原的组合物和方法
公开(公告)号：US07947272B2
公开(公告)日：2011-05-24
申请号：US11486293
申请日：2006-07-13
申请人： Mark Frewin , Herman Waldmann , Scott Gorman , Geoff Hale , Patricia Rao , Tadeusz Kornaga , Douglas Ringler , Stephen Cobbold , Dawn Winsor-Hines
发明人： Mark Frewin , Herman Waldmann , Scott Gorman , Geoff Hale , Patricia Rao , Tadeusz Kornaga , Douglas Ringler , Stephen Cobbold , Dawn Winsor-Hines
IPC分类号： A61K39/395
CPC分类号： C07K16/2812 , A61K39/39541 , A61K2039/505 , A61K2039/507 , C07K14/70514 , C07K16/00 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , A61K2300/00
摘要： Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.
摘要翻译：通过使用在体外测试时具有某些特征的化合物或至少两种化合物的组合来诱导灵长类动物的耐受性。单独或组合的化合物优选为TRX1抗体，并且优选根据指定的给药方案使用所述化合物或组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式